Cyclosporine Ophthalmic Suspension [Restasis]
National Institutes of Health
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
Cell penetrating peptide (CPP), LK-3, causes a ca. 10-fold increase in the cell penetration of cyclosporin A (CsA) at nanomolar…
Zusammenfassung Hintergrund Alterung ist ein wichtiger, bislang in Bezug auf therapeutische Maßnahmen jedoch nur unzureichend ber…
Restasis® is the only ophthalmic medication containing cyclosporine A that is registered in the Russian Federation. According to…
The purpose of the study was to evaluate the efficacy and acceptability of the drug Restasis® in treatment of atopic…
The impact of dry eye disease on patient’s health, visual function and quality of life may be substantial. At present, the only…
PURPOSE
This retrospective, clinical comparative analysis describes differences in clinical signs and symptoms and medication…
Purpose: We conducted a study to evaluate the change of tear secretion and symptoms in the patients with dry eye syndrome after…